Last week Cellular Dynamics International (CDI) and Life Technologies announced a partnership to commercialize a set of three novel products that are optimized to consistently develop and grow human induced pluripotent stem (iPS) cells for both research and bioproduction purposes. This partnership combines CDI’s leadership in human iPS cell development and manufacturing as well as Life Technologies’ expertise in the commercialization of stem cell research tools
By creating a consistent, defined reagent system, these products overcome the limitations associated with commonly-used stem cell culture products, such as bovine serum albumin (BSA) and lipids, by reducing the variability in results inherent with other reagents. Generating consistent performance supports the advancement of translational stem cell research and drug discovery efforts. These products also further research efforts by enabling large-scale production of human iPS cells to be conducted.
Recent studies published in Nature Methods and PLoS One validated the effectiveness of CDI’s products, and presentations by customers of studies using the company’s human iPS cells at the Society of Toxicology (SOT) Annual Meeting demonstrated the superiority of CDI’s products compared to other cell models.
In addition, CDI was named last year’s overall Gold winner in The Wall Street Journal Technology Innovation Awards based on the ability of its iPS cell manufacturing technology to facilitate understanding of human biology, improve the drug discovery process and develop cell-based therapies to treat human diseases.
Read more about The Wall Street Journal Technology Innovation Awards in the following article:
The Wall Street Journal
Receiving an award is a great way for a company to raise its profile and
gain recognition for its technology or therapeutic. Throughout the year multiple award programs are applicable to our clients, including The Scientist’s Top 10 Innovations, the MIT International Technology Awards and the honor our client CDI received this week, The Wall Street Journal’s 2011 Technology Innovation Gold Award.
Before Russo Partners begins the process of submitting a client for consideration for an award, several criteria must first be met. It is important to understand the award and what is needed in order to be considered. What is the publication looking for? What does a company need to have in order to qualify? This can also be determined by looking at past winners and verifying that the company is similar to others in the category; for instance, you might consider whether a company also has an innovative technology in the vein of a past winner or is comparable in size to one that came before.
Secondly, the award must support the client’s communications objectives. Will this award benefit perception? Is the award credible? An award from The Wall Street Journal or The Scientist is highly regarded by others in the investment and scientific communities and is undoubtedly beneficial for our clients. Receiving an award from a prestigious publication raises awareness and adds validation to the technology or therapeutic being recognized.
As CDI’s recent recognition demonstrates, when all of these pieces are in place, the payoff is certainly worth it.
Below are links to The Wall Street Journal article about the winners, the article profiling CDI and a video describing the winners.
The Wall Street Journal Article About the Winners
The Wall Street Journal Article Profiling CDI
Wall Street Journal Video Describing the Winners
Posted in Uncategorized
Tagged Awards, best practices, CDI, Cellular Dynamics International, innovation, public relations, Russo Partners, strategy, Technology, Technology Innovations Awards, Wall Street Journal, WSJ